Previous close | 2.0900 |
Open | 1.9500 |
Bid | 1.7900 |
Ask | 1.9700 |
Strike | 27.50 |
Expiry date | 2024-09-20 |
Day's range | 1.8000 - 1.9600 |
Contract range | N/A |
Volume | |
Open interest | 8.66k |
Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.
Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.
The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.